4.6 Article

Developing New Drug Treatments in the Era of Network Medicine

Journal

CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 93, Issue 1, Pages 26-28

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2012.207

Keywords

-

Funding

  1. National Institutes of Health (NIH) [HL113264, HL075478, HL105339, HL089856, HL083069, HL061795, HL048743, HL107192, HL070819, HL108630]
  2. NHLBI
  3. GlaxoSmithKline
  4. AstraZeneca
  5. Merck

Ask authors/readers for more resources

Although impressive advances have been made in determining the genetic and molecular causes of disease, treatment for many complex diseases remains inadequate. Despite compelling unmet medical needs and new insights into disease pathobiology, new drug approvals for complex diseases have stagnated. A new paradigm for drug development is needed, and key concepts from network medicine and systems pharmacology may be essential to this effort.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available